Why Countries Are Racing to Build mRNA Factories While America Hesitates on Next-Gen Vaccines
BioSpace · BioSpace
Audio is streamed directly from the publisher (api.riverside.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This episode continues the discussion regarding the rapid evolution of mRNA technologies since COVID-19. Guests discuss the improvements that have occurred within just a few years, which are making these therapies more reliable, cost-effective and viable for personalized cancer, rare disease chronic disease treatment.
Today’s episode is sponsored by Eclipsebio. From AI-ready datasets to sequencing validation, they drive RNA success.
Explore their solutions at https://eclipsebio.com/.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Andy Geall, Co-founder and Chief Development Officer, Replicate Bioscience; Chair of the Board, Alliance for mRNA Medicines
Pad Chivukula, Co-founder, CSO & COO, Arcturus Therapeutics
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.